OMB APPROVAL
OMB Number: 3235-0145
Expires: December 31, 2005
Estimated average burden
hours per response........11
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. _____)*
Neurogen Corporation
--------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, $0.025 par value
--------------------------------------------------------------------------------
(Title of Class of Securities)
64124E
-----------------------------------------------------------------
(CUSIP Number)
January 13, 2004
-----------------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
[ ] Rule 13d-1(b)
[X] Rule 13d-1(c)
[ ] Rule 13d-1(d)
* The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
CUSIP NO. 64124E 13G PAGE 2 OF 7 PAGES
--------------------------------------------------------------------------------
1 NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Merck & Co., Inc.
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (A) [ ]
(B) [ ]
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
New Jersey
--------------------------------------------------------------------------------
NUMBER OF 5 SOLE VOTING POWER
SHARES 1,783,252
----------------------------------------------------------
BENEFICIALLY 6 SHARED VOTING POWER
OWNED BY 0
----------------------------------------------------------
EACH 7 SOLE DISPOSITIVE POWER
REPORTING 1,783,252
----------------------------------------------------------
PERSON 8 SHARED DISPOSITIVE POWER
WITH 0
--------------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,783,252
--------------------------------------------------------------------------------
10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(SEE INSTRUCTIONS) [ ]
--------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
9.0%
--------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
CO
--------------------------------------------------------------------------------
CUSIP NO. 64124E 13G PAGE 3 OF 7 PAGES
--------------------------------------------------------------------------------
1 NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Merck Sharp & Dohme, Ltd.
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (A) [ ]
(B) [ ]
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
England
--------------------------------------------------------------------------------
NUMBER OF 5 SOLE VOTING POWER
SHARES 1,783,252
----------------------------------------------------------
BENEFICIALLY 6 SHARED VOTING POWER
OWNED BY 0
----------------------------------------------------------
EACH 7 SOLE DISPOSITIVE POWER
REPORTING 1,783,252
----------------------------------------------------------
PERSON 8 SHARED DISPOSITIVE POWER
WITH 0
--------------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,783,252
--------------------------------------------------------------------------------
10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(SEE INSTRUCTIONS) [ ]
--------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
9.0%
--------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
CO
--------------------------------------------------------------------------------
Page 4 of 7 Pages
ITEM 1.(A) NAME OF ISSUER
Neurogen Corporation
ITEM 1.(B) ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES
35 Northeast Industrial Road
Branford, Connecticut 06405
ITEM 2. (A) NAME OF PERSON FILING
This Schedule 13G is being filed on behalf of the following persons (the
"Reporting Persons"):
(i) Merck & Co., Inc.
(ii) Merck Sharp & Dohme, Ltd. ("MSD")
ITEM 2. (B) ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE.
Merck & Co., Inc.
One Merck Drive
Whitehouse Station, New Jersey 08889-0100
Merck Sharp & Dohme, Ltd.
Hertford Road, Hoddesdon
Herts., England EN11 9BU
ITEM 2. (C) CITIZENSHIP
See Item 4 of the attached cover pages.
ITEM 2. (D) TITLE OF CLASS OF SECURITIES
Common Stock, par value $0.025 per share.
ITEM 2. (E) CUSIP NUMBER.
64124E
ITEM 3.
Not applicable as this Schedule is filed pursuant to Rule 13d-1(c).
Page 5 of 7 Pages
ITEM 4. OWNERSHIP.
(a) Amount beneficially owned:
See Item 9 of the attached cover pages.
(b) Percent of class:
See Item 11 of the attached cover pages.
(c) Number of shares as to which such person has:
(i) Sole power to vote or to direct the vote:
See Item 5 of the attached cover pages.
(ii) Shared power to vote or to direct the vote:
See Item 6 of the attached cover pages.
(iii) Sole power to dispose or to direct the disposition:
See Item 7 of the attached cover pages.
(iv) Shared power to dispose or to direct the disposition:
See Item 8 of the attached cover pages.
ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
Not Applicable.
ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
Not Applicable.
ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED
THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
Not Applicable.
ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
Not Applicable.
ITEM 9. NOTICE OF DISSOLUTION OF GROUP.
Not Applicable.
Page 6 of 7 Pages
ITEM 10. CERTIFICATION.
By signing below I certify that, to the best of my knowledge and belief, the
securities referred to above were not acquired and are not held for the purpose
of or with the effect of changing or influencing the control of the issuer of
the securities and were not acquired and are not held in connection with or as a
participant in any transaction having that purpose or effect.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Dated: January 22, 2004
MERCK & CO., Inc.
By: /s/ Celia A. Colbert
-------------------------------------
Name: Celia A. Colbert
Title: Vice President, Secretary and
Assistant General Counsel
MERCK SHARP & DOHME, LTD.
By: /s/ Marc C. Dalby
---------------------
Name: Marc C. Dalby
Title: Secretary